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A B S T R A C T   
Aims: Mental health symptoms are frequent in women with gestational diabetes mellitus (GDM) and may in-
fluence glycemic control. We therefore investigated if mental health symptoms (high depression and low well- 
being scores) predicted a need for glucose-lowering medication and if this use of medication influenced the 
trajectory of mental health during pregnancy and in the postpartum period. 
Methods: We included 341 pregnant women from a cohort of GDM women in a Swiss University Hospital. The 
World Health Organization Well-being Index-Five was collected at the first and last GDM and at the postpartum 
clinical visits and the Edinburgh Postnatal Depression Scale at the first GDM and the postpartum clinical visits. 
Medication intake was extracted from participants’ medical records. We conducted linear and logistic regressions 
with depression as an interaction factor. 
Results: Mental health symptoms did not predict a need for medication (all p ≥ 0.29). Mental health improved 
over time (both p ≤ 0.001) and use of medication did not predict this change (all p ≥ 0.40). In women with 
symptoms of depression, medication was associated with less improvement in well-being at the postpartum 
clinical visit (p for interaction=0.013). 
Conclusions: Mental health and glucose-lowering medication did not influence each other in an unfavourable way 
in this cohort of women with GDM.   
1. Introduction 
Gestational diabetes mellitus (GDM) is defined as a glucose intoler-
ance diagnosed in the second or third trimester of pregnancy that does 
not fulfil the criteria of overt diabetes (Cefalu et al., 2019). Lifestyle 
interventions focusing on diet and physical activity are usually recom-
mended as the primary therapeutic strategy (Blumer et al., 2013; Gilbert 
et al., 2019; Cefalu et al., 2019; American Diabetes Association, 2020) 
for glucose control during pregnancy. When lifestyle interventions fail to 
achieve glycemic targets (Lehmann et al., 2009; Blumer et al., 2013; 
Metzger et al., 2007; American Diabetes Association, 2020), 
glucose-lowering medication is initiated. In accordance with the 
American Diabetes Association (ADA) guidelines, insulin is prescribed 
more frequently in Switzerland, as it does not cross the placenta (Cefalu 
et al., 2019; American Diabetes Association, 2020), although metformin 
can also be prescribed (Webber et al., 2015). According to a recent study 
and similarly to our practice, insulin is the most frequently used 
glucose-lowering medication during GDM pregnancy across countries 
(Cesta et al., 2019). 
Women with GDM are more likely to suffer from mental health 
symptoms. Indeed, women with GDM have higher rates of depression 
during pregnancy and in the postpartum period, compared to women 
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without GDM (Bennett et al., 2004; Damé et al., 2017; Daniells et al., 
2003; Wilson et al., 2019; Alexandre et al., 2017). Mental health 
symptoms therefore represent an important factor to consider in women 
with GDM, as they may interfere with their capacity to adhere to life-
style interventions (Molyneaux et al., 2018). Indeed, symptoms of 
depression may reduce an individual’s coping abilities and may lead to 
disordered eating behaviors and lower dietary quality (Fowles et al., 
2011). Depression may also lead individuals to eat as a strategy to 
relieve themselves of negative symptoms (Christenson et al., 2016) and 
may decrease women’s motivation to conduct physical activity (Carter 
and Swardfager, 2016). Thus, mental health symptoms may impact both 
diet and physical activity and lead to higher glycaemia during preg-
nancy (Blumer et al., 2013; Ruchat and Mottola, 2013). Secondly, 
mental health symptoms may be directly related to worsened metabolic 
control in women with GDM. Overall, depression is associated with a 
higher risk of future GDM (Hinkle et al., 2016). Similarly, higher anxiety 
and depression scores, as well as stress perception, are associated with 
higher glycaemia during pregnancy (Horsch et al., 2016; Hinkle et al., 
2016). However, even if mental health symptoms can have a direct 
impact on glycaemia and adherence to lifestyle interventions, it is not 
clear if it increases the need for glucose-lowering medication in women 
with GDM. In addition, we are not aware of any study investigating 
whether the presence of clinically relevant symptoms of depression 
might augment the need for glucose-lowering medication. This could 
have an important impact on the identification and care of these women. 
Conversely, there might also be an association between the need for 
glucose-lowering medication and subsequent mental health symptoms. 
Indeed, our clinical experience shows that many women are willing to 
adjust their lifestyle in order to avoid medication and particularly the 
burden of insulin injections. In addition, the need for glucose-lowering 
medication could lead to a feeling of failure. To our knowledge, only 
one study showed that insulin use was not a predictor for postpartum 
depression in women with GDM (Nicklas et al., 2013). Thus, the po-
tential impact of glucose-lowering medication on the mental health of 
women with GDM and in the postpartum period remains understudied. 
It is important to study this question, as mental health symptoms have 
been shown to be higher in the postpartum period in women with GDM 
(Wilson et al., 2019) and may have important adverse effects on the 
health of the mother (Christenson et al., 2016; Herring et al., 2008) and 
the infant (Grace et al., 2003; Cooper and Murray, 1998; Cato et al., 
2019). To study these questions, we chose both symptoms of depression 
(Hinkle et al., 2016; Blumer et al., 2013; Ruchat and Mottola, 2013) and 
well-being (Robertson et al., 2012; Hochberg et al., 2012) as markers of 
mental health, as they had either shown their impact on glycemic con-
trol or were studied in patients with diabetes. 
This study was therefore conducted to 1) investigate if mental health 
symptoms, described here as high symptoms of depression and low well- 
being scores, in women with GDM, predict a need for glucose-lowering 
medication during pregnancy and 2) describe the overall trajectory of 
mental health in these women and investigate if the need for glucose- 
lowering medication independently predicts mental health symptoms 
during and after pregnancy. We also studied if clinically relevant 
symptoms of depression would influence these associations, i.e., if they 
are different in the presence of symptoms of depression. 
2. Materials and methods 
2.1. Setting and patient population 
This prospective clinical cohort study included pregnant women 
diagnosed with GDM according to the International Association of the 
Diabetes and Pregnancy Study Groups (IADPSG) and ADA guidelines 
(Metzger et al., 2010; Blumer et al., 2013; American Diabetes Associa-
tion, 2019). These women were taken care of in the Diabetes and 
Pregnancy Unit at the Lausanne University Hospital (Switzerland) be-
tween 2016 and 2019. The Human Research Ethics Committee of the 
Canton de Vaud, Switzerland approved the study protocol (326/15). 
2.2. Inclusion and exclusion criteria 
This study is part of an ongoing prospective clinical cohort of women 
with GDM, for which participating women provided signed consent for 
data usage. Out of the 959 participating women, we selected those who 
corresponded to our eligibility criteria (n = 875) (please see Fig. 1), who 
presented after January 2016 (when we started systematically distrib-
uting mental health questionnaires) (n = 800), and were present during 
predefined time points that are essential (first and last GDM visit) in 
order to have baseline mental health assessed and valid information 
regarding glucose-lowering medication (the two main aims of the 
study). Thus, 341 women with GDM were included in the current 
analysis. 
2.3. GDM management/clinical care 
At the first clinical visit after the confirmation of GDM diagnosis, 
women receive information on GDM from a nurse or medical doctor 
specialized in GDM and are taught to perform capillary blood glucose 
(CBG) measures. Women are then asked to monitor their CBG 4 times 
per day (fasting blood glucose (FBG) in the morning and 2-hour (or 1- 
hour) postprandial blood glucose after each meal) (Arditi et al., 2017; 
American Diabetes Association, 2020). A week later, women are seen by 
a dietician and receive recommendations regarding their CBG, eating 
habits and weight gain (Blumer et al., 2013) and are encouraged to in-
crease their physical activity (Colberg et al., 2013). If despite lifestyle 
changes (diet and physical activity) glucose values remain above targets 
two or more times during a 1–2-week period, glucose-lowering medi-
cation is introduced (Lehmann et al., 2009; Metzger et al., 2007). 
Glucose-lowering medication type depends on glucose values (i.e., in-
sulin in case of relatively high values), patient characteristics (i.e., Body 
Mass Index (BMI)) and patient preference, but in the vast majority of 
cases insulin is the preferred treatment over metformin. Short-acting 
insulin analogues are introduced and adapted to achieve a 2-hour 
postprandial glucose value ≤7 mmol/l (alternatively 1-hour post-
prandial glucose ≤8 mmol/l), and long-acting insulin analogues to 
achieve FBG ≤5.3 mmol/l (Carroll and Kelley, 2014; American Diabetes 
Association, 2019, 2020). Women are then followed until delivery and 
an oral glucose tolerance test (oGTT) is performed between 6 and 8 
weeks postpartum (American Diabetes Association, 2020). 
2.4. Measures 
2.4.1. Maternal symptoms of depression 
The Edinburgh Postnatal Depression Scale (EPDS): The EPDS was used 
in the current study to measure symptoms of depression. The ques-
tionnaire has been validated in pregnant women (Bunevicius et al., 
2009), as well as in a French population, and good psychometric prop-
erties have been reported (Guedeney and Fermanian, 1998). Symptoms 
of depression in the preceding 7 days were assessed (Cox, Holden, and 
Sagovsky, 1987) at the women’s first GDM clinical visit and at the 6–8 
weeks postpartum clinical visit. We distributed this self-report ques-
tionnaire in French and in English. For women who did not understand 
these languages, we ensured that a certified professional translator 
helped them complete it. Each item of this questionnaire is scored on a 
4-point scale, the minimum and maximum total scores being 0 and 30, 
respectively. For our interaction analysis, we additionally created a 
dichotomous variable using a cut-off of ≥ 11 to separate women with 
and without clinically relevant depression scores (Bunevicius et al., 
2009). For this cut-off, the terminology “clinically relevant symptoms of 
depression” was chosen, given that clinical interviewing represents the 
gold standard to diagnose depression (Watson et al., 2009). 
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2.4.2. Maternal well-being index 
The World Health Organisation Well-Being Index-Five (WHO-5): The 
WHO-5 was used to measure well-being in our sample, as this ques-
tionnaire has shown adequate validity as an outcome measure in clinical 
studies (Henkel et al., 2003; Topp et al., 2015). It has been used 
extensively in endocrinology, and the French version has shown good 
psychometric properties (Topp et al., 2015; Hochberg et al., 2012). This 
5-item self-report questionnaire assessed the subjective well-being of the 
participants (Topp et al., 2015) at the first and last GDM clinical visit and 
at the 6–8 weeks postpartum clinical visit. In accordance with the 
ethnical diversity of our patients, we used validated versions of the 
questionnaire in several languages. The items are measured on a 5-point 
Likert scale ranging from 0 ‘at no time’ to 5 ‘all of the time’. The final score 
is then calculated by multiplying the total score by 4; thus, the final 
score ranges from 0 to 100. 
2.4.3. Glucose-lowering medication 
Information regarding glucose-lowering medication intake was 
retrieved from the medical records at the last GDM clinical visit. With 
this information, two types of variables were generated. First, a 
dichotomous (yes, no) variable named “glucose-lowering medication” 
was created to know if women did or did not take glucose-lowering 
medication during their pregnancy. For additional and more detailed 
analysis, a second variable was comprised of four categories: no glucose- 
lowering medication intake (1), metformin only (2), long-acting (basal) 
bedtime insulin ( ± metformin) (3), and short-acting (meal) insulin 
( ± long-acting bedtime insulin and/or metformin) (4). These categories 
of glucose-lowering medication were formed based on degrees of burden 
to the participants: the injections with short-acting insulins were 
considered being most burdensome (as women have to carry syringes 
with them wherever they go and inject before the meals, often outside of 
their home), and no glucose-lowering medication, was considered as 
putting a lower strain on women and metformin was in between. Indeed, 
previous research has shown that metformin is better accepted in 
women with GDM and that insulin is more burdensome (Rowan et al., 
2008). This variable is named “detailed glucose-lowering medication” 
and the reference category was 1 =no glucose-lowering medication 
intake. 
2.4.4. Sociodemographic, medical and anthropometric variables 
At the first GDM clinical visit, maternal age, weeks of gestation, 
educational level, social support, prior GDM diagnosis, and family his-
tory of diabetes information were collected during the clinical consul-
tation or extracted from medical records. Furthermore, glycated 
haemoglobin (HbA1c) was measured using a chemical photometric 
method (conjugation with boronate; Afinion®) (Clinical Chemistry and 
Clinical Toxicology Devices Panel, 2016; Wood et al., 2012) and Body 
Mass Index (BMI) at first GDM clinical visit was calculated based on 
measured height and weight using the formula weight (kg)/[height 
(m)]2. 
2.5. Data analysis 
All analyses were carried out with SPSS (IBM Corp. Released 2017. 
IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). 
Descriptive statistics were conducted for socio-demographic variables 
(Table 1). Continuous and normally distributed variables were described 
as means and standard deviations and ordinal outcomes were described 
as frequencies and percentages. Statistical significance was set at 
p < 0.05. 
Regarding the first objective, investigating the prospective associa-
tion between mental health symptoms and the subsequent need for 
glucose-lowering medication, we conducted logistic regression analyses 
with the dichotomous glucose-lowering medication variable as the 
dependent variable. To see if this relationship was different in women 
with higher depression scores, we added the “clinically relevant symp-
toms of depression” interaction term (dichotomous variable created 
from the EPDS scale) for the association between well-being and the 
glucose-lowering medication dichotomous variable. This was possible, 
as the correlation between the predictor (well-being scores) and the 
interaction term (clinically relevant symptoms of depression) was only 
small to moderate (correlation coefficient r = − 0.47). This interaction 
term could not be added when the depression scores were the predictor, 
as the correlation was too high between this predictor and the 
Cohort popula on with 
signed consent 

















Assessed for eligibility 
criteria (n = 959)
Excluded:
1. Known type 1 diabetes, Pre-
exis etes, GDM at 
≤13 weeks, Diabetes diagnosed 
during pregnancy, Normal HGPO 
results, Glucose intolerance but 
no GDM (n=24) 
2. Par cipa ng in an ac ve 
interven on group of an RCT 
(n=54) 
3. Age ≤ 18 years (n=6)







Assessed for presence of 




 Absence at first or last GDM 
clinical visit (n=75) 
2.
First GDM clinical visit before 
the 01.01.16 (n=459) 
Fig. 1. Flow chart describing how the study 
participants were selected. * Systematic distri-
bution of mental health questionnaires started 
on 01.01.2016 and women that were followed 
before this time point were excluded. First and 
last GDM clinical visit were the predefined 
essential time points providing indispensable 
information regarding the two main aims: 
baseline mental health and valid information 
regarding glucose-lowering medication. 
Women that were absent at either one of these 
time points were therefore also excluded.   
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interaction term (clinically relevant symptoms of depression; correlation 
coefficient r = 0.81) and both of these measures; depression scores and 
clinically relevant symptoms of depression are derived from the same 
questionnaire. Given that none of the interactions were significant in our 
first objective, we did not conduct further stratification analyses. 
Regarding the second objective, we first evaluated the trajectory of 
the depression and well-being scores over time during and after preg-
nancy in women with GDM using a linear mixed effects model. Indeed, it 
seemed important to first gain knowledge about the general trajectory of 
mental health in women with GDM in pregnancy and in the postpartum 
period. Then, we assessed the prospective association between the use of 
glucose-lowering medication and subsequent mental health at the end of 
pregnancy (well-being scores) and in the postpartum period (well-being 
and depression scores). We performed linear regressions with occur-
rence of glucose-lowering medication as a binary predictor (yes, no), 
and also with the detailed glucose-lowering medication as a categorical 
predictor. Finally, to see if the impact of glucose-lowering medication 
(yes, no) on mental health was different if clinically relevant symptoms 
of depression were present, we added the “clinically relevant symptoms 
of depression” interaction term. If any of the interactions were signifi-
cant, we conducted further stratification analyses, separating women 
with clinically relevant symptoms of depression from those without. 
This was only the case for the association between the dichotomous 
glucose-lowering medication variable during pregnancy and well-being 
at the postpartum clinical visit. 
For all regressions, we used two models (model 1 & 2). In model 1, 
we adjusted for maternal age and gestational weeks at the first GDM 
clinical visit (Crowther et al., 2005; Ruohomäki et al., 2018). In model 2, 
we added variables that were significantly correlated with the respective 
dependent variable. We tested the following potential confounder var-
iables: family history of diabetes, prior GDM diagnosis, BMI and HbA1c 
at the first GDM clinical visit, social support, and educational level. For 
the first objective, family history of diabetes, social support, educational 
level, and HbA1c were added as confounders in model 2. For the second 
objective, only family history of diabetes was added as a confounder in 
model 2 when the dependent variable was well-being. There was no 
model 2 when the dependent variable was depression, as none of the 
additional confounders were correlated with this score. In an additional 
step, we also adjusted for baseline mental health variables at the first 
GDM clinical visit in order to investigate if the associations changed. 
Given that this did not change the results (data not shown), we used the 
simpler model (model 2). In analogy, we also tested completely unad-
justed models. However, as is common practice, we adjusted for age and 
gestational age in our basic model 1. 
3. Results 
Table 1 shows detailed descriptive information regarding socio-
demographic and medical parameters. Women had a mean age of 
33.62 ± 5.34 years and a mean gestational age of 28.85 ± 3.38 weeks at 
the first GDM clinical visit and a mean gestational age of 36.44 ± 1.28 at 
the last GDM clinical visit. 25.2% of women suffered from clinically 
relevant symptoms of depression and 47.8% of women took glucose- 
lowering medication during their GDM pregnancy. In our sample, 120 
(35.2%) women were pregnant for the first time and 167 (49%) had no 
previous babies. Out of 174 (51%) women who were multiparas, 9.2% 
(n = 16) had previous GDM. 
3.1. Prospective associations between mental health and the subsequent 
need for glucose-lowering medication during pregnancy 
Women’s mental health at the first GDM clinical visit did not predict 
a subsequent need for glucose lowering medication during pregnancy, 
neither for the depression (OR=1.0 (CI=0.96 – 1.04; p = 0.94) nor for 
the well-being scores (OR=0.99 (CI=0.98–1.01; p = 0.29). These results 
remained similar in model 2 (OR=0.99 (CI=0.93 – 1.04; p = 0.62) and 
(OR=0.99 (CI=0.98 – 1.01; p = 0.30)). 
The association between the well-being score and the subsequent 
need for glucose-lowering medication was not significantly different 
between women with or without clinically relevant symptoms of 
depression at the first GDM clinical visit (p for interaction = 0.80). 
3.2. Prospective associations between the need for glucose-lowering 
medication and subsequent mental health during and after pregnancy 
Mental health improved significantly over time in the whole sample 
(see Fig. 2a & 2b). Thus, the depression scores decreased by 26% be-
tween the first GDM clinical visit and the postpartum clinical visit 
(B=− 1.74, CI= − 2.22 to − 1.26, p < 0.01). Specifically, mean scores 
changed from a 7.43 ± 5.46 at the first GDM clinical visit to 5.90 ± 4.40 
at the postpartum clinical visit. The well-being scores increased overall 
by 7% between the first GDM clinical visit and the postpartum clinical 
visit (B=2.49, CI= 1.34 – 3.64, p < 0.01). More specifically, the mean 
Table 1 
Descriptive maternal sociodemographic and medical parameters.   







Mean (SD) or 
n (%) 
Mean (SD) or n 
(%) 
Mean (SD) or n 
(%) 
Maternal sociodemographic and medical parameters 
Age (years) 33.62 (5.34) 33.39 (5.27) 33.84 (5.41) 
Educational level    
No education 3 (0.9%) 1 (0.6%) 2 (1.1%) 
Compulsory education not 
completed 
17 (5%) 8 (4.9%) 9 (5.1%) 
Compulsory education 
completed 
60 (17.6%) 33 (20.3%) 27 (15.2%) 
Secondary school 38 (11.1%) 18 (11%) 20 (11.2%) 
Apprenticeship 55 (16.1%) 29 (17.8%) 26 (14.6%) 
University degree 113 (33.1%) 46 (28.2%) 67 (37.6%) 
Social support    
Lives: alone without 
support, alone with 
support, with partner 
13 (3.8%), 14 
(4.1%), 292 
(85.6%) 
9 (5.5%), 2 
(1.2%), 138 
(84.7%) 
4 (2.2%), 12 
(6.7%), 154 
(86.5)* 
Obstetric variables    
Gestational age at first GDM 
clinical visit 
28.85 (3.38) 28.13 (3.85) 29.51 (2.74)* 
Gestational age at last GDM 
clinical visit 
36.44 (1.28) 36.34 (1.31) 36.53 (1.25) 
GDM variables    
HbA1c at first GDM clinical 
visit % - (mmol/mol) 
5.4 (0.43) – 
(35 (4.32)) 
5.5 (0.51) – 
(37 (5.09)) 
5.3 (0.31) (34 
(3.11))* 
Family history of diabetes: 





56 (34.4%), 63 
(38.7%), 33 
(20.2%) 
70 (39.2%), 59 
(33.1%), 38 
(21.3%) 
Mental health variables    
Depression score at first 
GDM clinical visit 
7.43 (5.46) 7.49 (5.75) 7.38 (5.20) 
Women with clinically 
relevant symptoms of 
depression (cut-off of ≥
11) at the first GDM 
clinical visit 
77 (25.2%) 42 (28.8%) 35 (22%) 
Detailed glucose-lowering medication for the overall sample  
n (%)  
No glucose-lowering medication intake (1) 178 (52.2%)  
Metformin only (2) 15 (4.4%)  
Long-acting (basal) bedtime insulin 
(±metformin) (3) 
64 (18.8%)  
Short-acting (meal) insulin (±long-acting 
bedtime insulin and/or metformin) (4) 
84 (24.6%)  
Continuous and normally distributed variables were described as means and 
standard deviations and ordinal outcomes were described as frequencies and 
percentages. *Indicates a significant difference (p < 0.05) between the sub-
groups with and without glucose-lowering medication, respectively. 
BMI: body mass index. 
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well-being scores changed from 60.55 ± 20.368 at the first GDM clinical 
visit to 67.59 ± 17.96 at the last GDM clinical visit, and to 
65.43 ± 18.79 at the postpartum clinical visit. 
The need for glucose-lowering medication during pregnancy had no 
impact on subsequent mental health during and after pregnancy. This 
was the case for the depression scores at the postpartum clinical visit 
(B=0.29 (CI=− 0.76 to 1.34; p = 0.59)), the well-being scores at the end 
of pregnancy (B=2.01 (CI=− 6.72 to 2.69; p = 0.40) in model 1, B= 2.26 
(CI=− 6.84 to 2.32; p = 0.33) in model 2) and the well-being scores at 
the postpartum clinical visit (B=− 0.15 (CI=− 4.59 to 4.30; p = 0.95) in 
model 1, B= 0.25 (CI=− 4.18 to 4.69; p = 0.91) in model 2). These re-
sults remained unchanged when controlled for baseline mental health at 
the first GDM clinical visit (data not shown). 
When looking at the detailed glucose-lowering medication, we found 
very similar results (see Table 2), with the exception of metformin, used 
in 13 women, that was associated with improved well-being in the 
postpartum period compared to no glucose-lowering medication 
(p = 0.03, see Table 2). 
Regarding the interaction effect of clinically relevant symptoms of 
depression on the association between glucose-lowering medication and 
mental health, we found no interaction effect on the depression score at 
the postpartum clinical visit (p = 0.93), nor on the well-being score at 
the end of pregnancy (p = 0.49). However, in women with clinically 
relevant symptoms of depression, glucose-lowering medication in 
pregnancy was associated with a lower improvement in the well-being 
score at the postpartum clinical visit compared to women without 
clinically relevant symptoms of depression (p for interaction = 0.01, 
Fig. 2b). Further stratification analysis revealed that, in women with 
clinically relevant symptoms of depression, glucose-lowering medica-
tion led to a non-significant decrease in well-being of − 8.82 points 
(p = 0.063), whereas in women without symptoms of depression, 
glucose-lowering medication lead to a non-significant increase in the 
well-being scores of 4.02 points (p = 0.12). 
4. Discussion 
This study investigated a clinical cohort of women with GDM and 
demonstrated that mental health symptoms at the first GDM clinical visit 
did not predict a later need for glucose-lowering medication. Further-
more, mental health improved throughout pregnancy and in the early 
postpartum period. Importantly, the need for glucose-lowering 
medication was not associated with future mental health symptoms 
during and after pregnancy. Clinically relevant symptoms of depression 
at the first GDM clinical visit did not interact with these investigated 
associations, except for the well-being scores at the postpartum clinical 
Fig. 2. Overall effect of time showing significant decreases in mean depression (Fig. 2a; Edinburgh Postnatal Depression Scale (EPDS)) and well-being (Fig. 2b; World 
Health Organization Well-being Index-Five; (WHO-5)) scores in the overall sample (B=− 1.74, CI= − 2.22 to –1.26, p < 0.01 and B=2.49, CI= 1.34 – 3.64, p < 0.01). 
For illustrative purposes, women with and without glucose-lowering medication are separated. Of all interaction effects tested, the only significant finding relates to 
the presence or not of clinically relevant symptoms of depression (named "depression" in the figures) at the first GDM visit on the association between glucose- 
lowering medication in pregnancy and well-being at the postpartum visit (p for interaction = 0.01 and shown as a star on Fig. 2b). Values are shown as means 
and standard errors. 
Table 2 
Prospective associations between detailed glucose-lowering medication during 
pregnancy and subsequent mental health.   
Model 1 Model 2  
Well-being scores at the last GDM clinical visit 
Metformin vs none B = − 0.62 (CI = − 11.66 to 
10.43) 
B = − 0.99 (CI = − 11.63 
to 9.65) 
Long-acting Insulin vs 
none 
B = − 2.95 (CI = − 8.86 to 
2.96) 
B = − 1.99 (CI= − 7.79 to 
3.82) 
Short-acting Insulin vs 
none 
B = − 0.54 (CI = − 6.22 to 
5.13) 
B = − 0.24 (CI= − 5.84 to 
5.36)  
Well-being scores at the postpartum clinical visit 
Metformin vs none B = 11.65 (CI = 1.06 – 
22.24)* 
B = 11.42 (CI = 0.92 – 
21.92)* 
Long-acting Insulin vs 
none 
B = − 1.97 (CI = − 7.60 to 
3.67) 
B = − 1.41 (CI = − 7.16 to 
4.34) 
Short-acting Insulin vs 
none 
B = 1.26 (CI = − 4.04 to 
6.55) 
B = 1.57 (CI = − 3.81 to 
6.95)  
Depression scores at the postpartum clinical visit 
Metformin vs none B = − 0.15 (CI = − 2.64 to 
2.34) 
– 
Long-acting Insulin vs 
none 
B = 1.00 (CI = − 0.34 to 
2.31) 
– 
Short-acting Insulin vs 
none 
B = 0.46 (CI = − 1.72 to 
0.80) 
– 
Results reported as β-Coefficient (95% confidence interval) from a general linear 
model. 
The following three categories are compared to “no glucose-lowering medica-
tion” (termed “none”) being used as a reference category (1), metformin only 
(2), long-acting (basal) bedtime insulin ( ± metformin) (3), and short-acting 
(meal) insulin ( ± long-acting bedtime insulin and/or metformin) (4). 
Model 1 adjusted for maternal age and gestational age at the first GDM clinical 
visit. 
Model 2 adjusted for maternal age, gestational age, family history of diabetes 
and well-being at the first GDM clinical visit, except for the analyses with the 
depression score at the postpartum clinical visit for which no additional con-
founders were added, as no additional confounders were significantly correlated 
to this dependent variable. 
* p < 0.05 
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visit, which improved less in women with clinically relevant symptoms 
of depression. 
To the best of our knowledge, this is the first study to report that 
there is no association between mental health symptoms and the sub-
sequent need for glucose-lowering medication in women with GDM. 
Previous research shows that mental health symptoms are associated 
with both a lower adherence to lifestyle interventions and thus can lead 
to higher glycaemia (Molyneaux et al., 2018; Carter and Swardfager, 
2016; Ruchat and Mottola, 2013), and, that mental health symptoms are 
also directly associated with a higher glycaemia in pregnancy (Hinkle 
et al., 2016; Horsch et al., 2016). Both, low adherence to lifestyle in-
terventions and higher glycaemia would be expected to lead to a more 
frequent need for glucose-lowering medication. Surprisingly, this was 
not the case in our population, nor was this influenced by the presence of 
clinically relevant symptoms of depression. These symptoms were pre-
sent in 25.2% of our cohort and the mean score was 7.43 at the first GDM 
clinical visit, which is comparable to other studies in women with GDM 
and, for some, in normal pregnancies (Damé et al., 2017; Varela et al., 
2017; Mak et al., 2019; Wilson et al., 2019). In our sample, the symp-
toms of depression declined by 26% to a mean score of 5.9 at the 
postpartum clinical visit. This score is similar to a previous sample of 
GDM women in the postpartum period (Nicklas et al., 2013). In the 
current sample, the well-being scores also augmented by 7% between 
the first GDM clinical visit and the postpartum clinical visit, and attained 
similar scores as previously reported in healthy pregnancies and in the 
postpartum period (Mortazavi et al., 2015). The scores at the last GDM 
clinical visit cannot be compared to previous research as we are not 
aware of such studies. The fact that well-being at the first GDM clinical 
visit and the postpartum clinical visit in our sample is not lower than 
that of normal pregnancies is reassuring, given that women with GDM 
usually have higher depression scores than the general population 
(Bennett et al., 2004; Damé et al., 2017), and that depression is known to 
be negatively associated with well-being in pregnancy (Wersebe et al., 
2018). We believe that the improvements found in mental health over 
time could be due to the social support the patients receive from clini-
cians (Barger et al., 2014). Indeed, women are seen a for a few clinical 
appointments during their pregnancy and receive tailored advice and 
attention from our team of specialized clinicians. This could also have 
improved well-being and lowered depression in our population, despite 
the need for frequent glucose monitoring and lifestyle adjustments. 
The improvements found in mental health were not influenced by 
glucose-lowering medication intake, as glucose-lowering medication did 
not predict the future well-being or depression scores during or after 
pregnancy. This result is comparable to one previous study in women 
with GDM showing that use of insulin during pregnancy was not asso-
ciated with symptoms of depression in the postpartum period (Nicklas 
et al., 2013), while overall well-being or mental health during preg-
nancy has not been previously investigated. These findings may reassure 
clinicians when they need to initiate glucose-lowering medication with 
patients, as mental health does not seem to be affected by medication 
intake, at least in our population. This could possibly mean that women 
do not view glucose-lowering medication as a failure of their lifestyle 
behavior change, but rather as another acceptable solution to lower 
their glucose. Also, glucose-lowering medication may bring them some 
relief if lifestyle adaptations alone did not yield the desired effect 
(Rowan et al., 2008). Another novel, yet, secondary finding was that the 
use of metformin was associated with improved well-being in the post-
partum period. Although, this result is in line with previous research 
showing that metformin is the preferred type of medication in women 
with GDM (Rowan et al., 2008), this result should be interpreted with 
caution and needs to be replicated in future research, as this concerned 
only a very small number of women (n = 13, 3.8%). 
The presence of clinically relevant symptoms of depression did not 
interact with our findings except with the association between glucose- 
lowering medication during pregnancy and the well-being scores in the 
postpartum period. Indeed, the results demonstrated that in women with 
both clinically relevant symptoms of depression and glucose-lowering 
medication, there was a lower improvement in the postpartum well- 
being scores compared to women with no clinically relevant symp-
toms of depression. In these women, the combination of glucose- 
lowering medication, higher depression scores and having to care for 
a newborn might cumulate and contribute to the lower increase and 
lower absolute well-being scores. Hajos et al. showed that a score of 50 
on the WHO-5, which is close to the mean score of 54 in our subgroup of 
women, can be interpreted as suboptimal well-being and warrants 
further testing for depression (Hajos et al., 2013). This is especially 
important, as depression in the postpartum period can have adverse 
impacts on the mother’s cardio-metabolic health (Christenson et al., 
2016; Herring et al., 2008; Carter and Swardfager, 2016). Depression in 
the postpartum may also lead to negative consequences for the infant, 
such as lower duration of breastfeeding (Cato et al., 2019) and to rela-
tionship difficulties between the mother and her infant, which have 
shown to be prospectively associated with a suboptimal development of 
cognitive (for example language development) and emotional func-
tioning of the infant (Grace et al., 2003; Cooper and Murray, 1998). 
Thus, these women should be identified and may need psychological 
interventions. 
4.1. Strengths and limitations 
This study has several strengths. First, we included a “real-life”, 
multiethnic and diverse population in which patients completed the 
questionnaires either in their native language or with the help of a 
certified professional translator. Second, we included influential con-
founding variables; in our basic model we controlled for variables of 
interest in the GDM population (Crowther et al., 2005; Ruohomäki et al., 
2018), and in our second model, we added confounding variables that 
correlated significantly to our dependent variables. Finally, we also 
made sure that the well-being and depression scores at the first GDM 
clinical visit did not alter the results by controlling for these results with 
a third model (data not shown). 
Limitations of the study include the lack of information about the 
women’s physical activity and diet behaviors, which could have been 
important confounders for the intake of glucose-lowering medication. 
Furthermore, we do not have information about mental health variables 
before the first GDM clinical visit or mental health measurements other 
than depression or well-being scores after their GDM diagnosis (such as 
anxiety symptoms), which could be seen as a limitation. The data about 
metformin needs to be interpreted with caution, as this only concerns 13 
(3.8%) of women and the choice to treat with metformin might be 
biased. As no exclusion criteria were applied for the timings of the 
clinical visits, this could have had an influence on the women’s mental 
health variables. Women came for their first GDM clinical visit at a mean 
of 28.85 (3.38) weeks of gestation. Allover, 8 (2.4%) women came 
before 20 or 24 weeks of gestation, as no women came between 20 and 
24 weeks of gestation and 29 (8.7%) came later than 32 weeks of 
gestation for their first GDM clinical visit. The last GDM clinical visit 
took place at a mean of 36.44 (1.28) weeks; all of the women came 
between 32 and 40 weeks of gestation and of those, 55 (23.7%) came 
before 36 weeks of gestation. We therefore performed the main analyses 
in a limited sample of 157 women who came between 24 and 32 weeks 
of gestation at the first GDM clinical visit and who were at 36 weeks of 
gestation or more at the last GDM clinical visit and the results did not 
significantly change. 
5. Conclusion 
This prospective clinical cohort study found that mental health 
symptoms did not lead to a higher subsequent need for glucose-lowering 
medication in women with GDM. This finding is reassuring, as it means 
that even if mental health symptoms can impact both on lifestyle 
behavior and on glycaemia, it does not necessarily implicate a higher 
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need for glucose-lowering medication. Secondly, glucose-lowering 
medication did not worsen the trajectory of mental health symptoms 
in this GDM population. This is reassuring for clinicians, as it demon-
strates that glucose-lowering medication can be prescribed without the 
risk of worsening mental health symptoms (symptoms of depression and 
lower well-being in particular). Even if mental health symptoms did not 
affect the need for glucose-lowering medication in our pregnant popu-
lation, it may influence lifestyle behavior and/or glucose values in the 
postpartum period and thus increase the risk of later prediabetes or 
diabetes. Similarly, further research should investigate, if the diagnosis 
of prediabetes and/or diabetes would worsen mental health symptoms 
in the following months and years and define the trajectory for such a 
change in order to intervene early. Further studies should also aim at 
investigating the relationship between use of medication and other 
mental health symptoms, such as anxiety in the GDM population. 
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